BRPI0710919A2 - derivados de diceto-piperazina e piperidina como agentes antivirais - Google Patents

derivados de diceto-piperazina e piperidina como agentes antivirais Download PDF

Info

Publication number
BRPI0710919A2
BRPI0710919A2 BRPI0710919-9A BRPI0710919A BRPI0710919A2 BR PI0710919 A2 BRPI0710919 A2 BR PI0710919A2 BR PI0710919 A BRPI0710919 A BR PI0710919A BR PI0710919 A2 BRPI0710919 A2 BR PI0710919A2
Authority
BR
Brazil
Prior art keywords
formula
original document
see original
document page
group
Prior art date
Application number
BRPI0710919-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Wang Tao
F. Kadow John
Zhang Zhongxing
Yin Zhiwei
A. Meanwell Nicholas
Requeiro-Ren Alicia
Swidorski Jacob
Han Ying
J. Carini David
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of BRPI0710919A2 publication Critical patent/BRPI0710919A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0710919-9A 2006-04-25 2007-04-16 derivados de diceto-piperazina e piperidina como agentes antivirais BRPI0710919A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US79470306P 2006-04-25 2006-04-25
US79470006P 2006-04-25 2006-04-25
US60/794,703 2006-04-25
US60/794,700 2006-04-25
US11/733,283 2007-04-10
US11/733,283 US7807671B2 (en) 2006-04-25 2007-04-10 Diketo-piperazine and piperidine derivatives as antiviral agents
PCT/US2007/066700 WO2007127635A2 (en) 2006-04-25 2007-04-16 Diketo-piperazine and piperidine derivatives as antiviral agents

Publications (1)

Publication Number Publication Date
BRPI0710919A2 true BRPI0710919A2 (pt) 2012-06-26

Family

ID=38335673

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0710919-9A BRPI0710919A2 (pt) 2006-04-25 2007-04-16 derivados de diceto-piperazina e piperidina como agentes antivirais

Country Status (17)

Country Link
US (2) US7807671B2 (cg-RX-API-DMAC7.html)
EP (1) EP2010525B1 (cg-RX-API-DMAC7.html)
JP (1) JP5214590B2 (cg-RX-API-DMAC7.html)
KR (1) KR101450349B1 (cg-RX-API-DMAC7.html)
AR (1) AR060658A1 (cg-RX-API-DMAC7.html)
AU (1) AU2007242989B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0710919A2 (cg-RX-API-DMAC7.html)
CA (1) CA2650382C (cg-RX-API-DMAC7.html)
EA (1) EA014957B1 (cg-RX-API-DMAC7.html)
ES (1) ES2432758T3 (cg-RX-API-DMAC7.html)
IL (1) IL194540A (cg-RX-API-DMAC7.html)
MX (1) MX2008013265A (cg-RX-API-DMAC7.html)
NO (1) NO341412B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ571995A (cg-RX-API-DMAC7.html)
PE (1) PE20080318A1 (cg-RX-API-DMAC7.html)
TW (1) TWI394754B (cg-RX-API-DMAC7.html)
WO (1) WO2007127635A2 (cg-RX-API-DMAC7.html)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US20050075364A1 (en) * 2003-07-01 2005-04-07 Kap-Sun Yeung Indole, azaindole and related heterocyclic N-substituted piperazine derivatives
US20060100209A1 (en) * 2004-11-09 2006-05-11 Chong-Hui Gu Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US20060100432A1 (en) * 2004-11-09 2006-05-11 Matiskella John D Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US7851476B2 (en) * 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
US7807671B2 (en) * 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
US7504399B2 (en) 2006-06-08 2009-03-17 Bristol-Meyers Squibb Company Piperazine enamines as antiviral agents
CA2687931C (en) * 2007-05-31 2016-05-24 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists and uses thereof
CA2695331A1 (en) * 2007-08-03 2009-02-12 F. Hoffmann-La Roche Ag Pyridinecarboxamide and benzamide derivatives as taar1 ligands
JP5433691B2 (ja) * 2008-06-25 2014-03-05 ブリストル−マイヤーズ スクイブ カンパニー Hiv結合阻害剤としてのジケトピペリジン誘導体
EP2303876B1 (en) * 2008-06-25 2014-03-19 Bristol-Myers Squibb Company Diketo azolopiperidines and azolopiperazines as anti-hiv agents
WO2010013849A1 (ja) * 2008-08-01 2010-02-04 日本ケミファ株式会社 Gpr119作動薬
CN102143739B (zh) * 2008-09-04 2014-12-17 百时美施贵宝公司 用于最优化传递hiv附着抑制剂的稳定的药用组合物
ES2551557T3 (es) 2008-12-19 2015-11-19 Boehringer Ingelheim International Gmbh Pirimidin-4-carboxamidas cíclicas como antagonistas del receptor CCR2 para el tratamiento de inflamaciones, asma y EPOC
JP5807971B2 (ja) 2009-04-27 2015-11-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Cxcr3受容体アンタゴニスト
PL2513093T3 (pl) 2009-12-17 2015-03-31 Centrexion Therapeutics Corp Nowi antagoniści receptora CCR2 i ich zastosowanie
US8952004B2 (en) 2010-01-07 2015-02-10 Boehringer Ingelheim International Gmbh CXCR3 receptor antagonists
TW201200518A (en) * 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
WO2011141474A1 (en) 2010-05-12 2011-11-17 Boehringer Ingelheim International Gmbh Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
EP2569295B1 (en) 2010-05-12 2014-11-19 Boehringer Ingelheim International GmbH New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
EP2571870B1 (en) 2010-05-17 2015-01-21 Boehringer Ingelheim International GmbH Ccr2 antagonists and uses thereof
US9018212B2 (en) 2010-05-25 2015-04-28 Boehringer Ingelheim International Gmbh Pyridazine carboxamides as CCR2 receptor antagonists
JP5721242B2 (ja) 2010-06-01 2015-05-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ccr2アンタゴニスト
JP5613461B2 (ja) * 2010-06-02 2014-10-22 日本農薬株式会社 ピリミジン誘導体及び該誘導体を含有する農園芸用殺虫剤並びにその使用方法
WO2011159794A1 (en) * 2010-06-17 2011-12-22 Bristol-Myers Squibb Company Deuterated hiv attachment inhibitors
EP2601174B1 (en) 2010-08-06 2014-11-26 Bristol-Myers Squibb Company Substituted indole and azaindole oxoacetyl piperazinamide derivatives
US8912195B2 (en) 2010-12-02 2014-12-16 Bristol-Myers Squibb Company Alkyl amides as HIV attachment inhibitors
WO2012142080A1 (en) * 2011-04-12 2012-10-18 Bristol-Myers Squibb Company Thioamide, amidoxime and amidrazone derivatives as hiv attachment inhibitors
JP5786258B2 (ja) 2011-07-15 2015-09-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規かつ選択的なccr2拮抗薬
US8859550B2 (en) 2011-09-12 2014-10-14 Kalypsys, Inc. Heterocyclic inhibitors of histamine receptors for the treatment of disease
WO2014025854A1 (en) * 2012-08-09 2014-02-13 Bristol-Myers Squibb Company Piperidine amide derivatives as hiv attachment inhibitors
JP6318156B2 (ja) * 2012-09-06 2018-04-25 プレキシコン インコーポレーテッドPlexxikon Inc. キナーゼをモジュレートするための化合物および方法、ならびにその指標
EA029056B1 (ru) * 2012-12-11 2018-02-28 Такеда Фармасьютикал Компани Лимитед Гетероциклическое соединение
MX364895B (es) 2013-03-13 2019-05-10 Forma Therapeutics Inc Nuevos compuestos y composiciones para la inhibicion de fasn.
EP2978762A1 (en) * 2013-03-27 2016-02-03 Bristol-Myers Squibb Company Piperazine and homopiperazine derivatives as hiv attachment inhibitors
US9586957B2 (en) * 2013-03-27 2017-03-07 VIIV Healthcare UK (No.5) Limited 2-keto amide derivatives as HIV attachment inhibitors
TR201807959T4 (tr) 2013-07-22 2018-06-21 Idorsia Pharmaceuticals Ltd 1-(Piperazın-1-il)-2- ([1,2,4] triazol-1-il)-etanon türevleri.
WO2015063709A1 (en) * 2013-10-31 2015-05-07 Ranbaxy Laboratories Limited Process for the preparation of 1-(3-methyl-1-phenyl-1h-pyrazol-5-yl)piperazine
WO2015190613A1 (en) * 2014-06-09 2015-12-17 Takeda Pharmaceutical Company Limited Radiolabeled compounds
RS58349B1 (sr) 2015-01-15 2019-03-29 Idorsia Pharmaceuticals Ltd Hidroksialkil-piperazinski derivati kao modulatori cxcr3 receptora
AR103399A1 (es) 2015-01-15 2017-05-10 Actelion Pharmaceuticals Ltd Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3
MX383744B (es) 2015-07-02 2025-03-14 Centrexion Therapeutics Corp Citrato de (4-((3r,4r)-3-metoxitetrahidro-piran-4-ilamino)piperidin-1-il) (5-metil-6-(((2r, 6s)-6-(p-tolil)tetrahidro-2h-piran-2-il) metilamino) pirimidin-4-il) metanona.
KR102014335B1 (ko) * 2017-12-01 2019-08-26 한국과학기술연구원 5-ht7 수용체의 조절제로 작용하는 아릴피라졸릴피페라진 또는 아릴피라졸릴다이아제페인의 유도체 및 이를 포함하는 중추신경계 질환 치료 또는 예방용 약학 조성물
CN113382633A (zh) 2018-10-29 2021-09-10 福马治疗股份有限公司 (4-(2-氟-4-(1-甲基-1H-苯并[d]咪唑-5-基)苯甲酰基)哌嗪-1-基)(1-羟基环丙基)甲酮的固体形式
GEAP202315648A (en) * 2018-11-02 2023-07-25 Merck Sharp & Dohme Llc 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors
CN111004213B (zh) * 2019-12-26 2021-07-20 北京欣奕华科技有限公司 一种有机电致发光化合物及其应用
TW202321229A (zh) * 2021-08-18 2023-06-01 美商富曼西公司 殺真菌的取代的雜環化合物
US20240208980A1 (en) * 2022-12-19 2024-06-27 Navinta, Llc Fostemsavir Intermediates and Process for the Preparation Thereof

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB944443A (cg-RX-API-DMAC7.html) 1959-09-25 1900-01-01
GB8615562D0 (en) 1986-06-25 1986-07-30 Maggioni Farma Aminoalcohols
WO1990007926A1 (en) 1989-01-20 1990-07-26 Pfizer Inc. 3-(1,2,5,6-tetrahydropyridyl)-pyrrolopyridines
US5023265A (en) 1990-06-01 1991-06-11 Schering Corporation Substituted 1-H-pyrrolopyridine-3-carboxamides
IL99843A0 (en) 1990-11-01 1992-08-18 Merck & Co Inc Synergistic combination of hiv reverse transcriptase inhibitors
US5811432A (en) 1990-11-09 1998-09-22 Pfizer Inc Azaoxindole derivatives
US5192770A (en) 1990-12-07 1993-03-09 Syntex (U.S.A.) Inc. Serotonergic alpha-oxoacetamides
KR100236808B1 (ko) 1991-07-03 2000-02-01 로렌스 티. 마이젠헬더 에이즈 치료약제로서의 치환된 인돌
US5124327A (en) 1991-09-06 1992-06-23 Merck & Co., Inc. HIV reverse transcriptase
WO1993005020A1 (en) 1991-09-06 1993-03-18 Merck & Co., Inc. Indoles as inhibitors of hiv reverse transcriptase
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
IT1265057B1 (it) 1993-08-05 1996-10-28 Dompe Spa Tropil 7-azaindolil-3-carbossiamidi
US5424329A (en) 1993-08-18 1995-06-13 Warner-Lambert Company Indole-2-carboxamides as inhibitors of cell adhesion
GB9420521D0 (en) 1994-10-12 1994-11-30 Smithkline Beecham Plc Novel compounds
TW429256B (en) 1995-12-27 2001-04-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-(benzimidazolyl- and imidazopyridinyl)-piperidine derivatives
US6172085B1 (en) 1996-08-29 2001-01-09 Takeda Chemical Industries, Ltd. Cyclic ether compounds as sodium channel modulators
DE19636150A1 (de) 1996-09-06 1998-03-12 Asta Medica Ag N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
AU1454599A (en) 1997-11-10 1999-05-31 Dana-Farber Cancer Institute Compounds inhibiting cd4-gp120 interaction and uses thereof
JP2002515891A (ja) 1997-12-19 2002-05-28 スミスクライン・ビーチャム・コーポレイション 新規なピペリジン含有化合物
IL137974A0 (en) 1998-03-26 2001-10-31 Shionogi & Co Indole derivatives having antiviral activity
DE19814838C2 (de) 1998-04-02 2001-01-18 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
JP2003521443A (ja) 1998-06-19 2003-07-15 ハー・ルンドベック・アクチエゼルスカベット 4,5,6及び7−インドール及びインドリン誘導体、その製造方法及びその使用方法
DE69934311D1 (de) 1998-06-30 2007-01-18 Lilly Co Eli BICYCLISCHE sPLA 2-INHIBITOREN
CA2342251A1 (en) 1998-08-28 2000-03-09 Scios Inc. Use of piperidines and/or piperazines as inhibitors of p38-alpha kinase
GB9905010D0 (en) 1999-03-04 1999-04-28 Merck Sharp & Dohme Therapeutic agents
HUP0201261A3 (en) 1999-05-21 2003-12-29 Scios Inc Sunnyvale Indole-type derivatives as inhibitors of p38 kinase and pharmaceutical compositions containing them
US6469006B1 (en) 1999-06-15 2002-10-22 Bristol-Myers Squibb Company Antiviral indoleoxoacetyl piperazine derivatives
TWI269654B (en) 1999-09-28 2007-01-01 Baxter Healthcare Sa N-substituted indole-3-glyoxylamide compounds having anti-tumor action
US20020061892A1 (en) 2000-02-22 2002-05-23 Tao Wang Antiviral azaindole derivatives
US6476034B2 (en) 2000-02-22 2002-11-05 Bristol-Myers Squibb Company Antiviral azaindole derivatives
US6573262B2 (en) 2000-07-10 2003-06-03 Bristol-Myers Sqibb Company Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives
WO2002004440A1 (en) 2000-07-10 2002-01-17 Bristol-Myers Squibb Company Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives
DE10037310A1 (de) 2000-07-28 2002-02-07 Asta Medica Ag Neue Indolderivate und deren Verwendung als Arzneimittel
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US20030207910A1 (en) 2001-02-02 2003-11-06 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
PL364279A1 (en) 2001-02-02 2004-12-13 Bristol-Myers Squibb Company Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US6825201B2 (en) 2001-04-25 2004-11-30 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic amidopiperazine derivatives
US6667378B2 (en) 2001-06-22 2003-12-23 L'oreal, S.A. Reshapable hair styling composition comprising heterogeneous (meth)acrylic copolymer particles
IL161667A0 (en) 2001-11-09 2004-09-27 Scios Inc Method and composition to treat cystic fibrosis
US20030236277A1 (en) 2002-02-14 2003-12-25 Kadow John F. Indole, azaindole and related heterocyclic pyrrolidine derivatives
WO2003082881A2 (en) 2002-03-28 2003-10-09 Procyon Biopharma Inc. Pyridoxal-5-phosphate derivatives as hiv integrase inhibitors
US7037913B2 (en) 2002-05-01 2006-05-02 Bristol-Myers Squibb Company Bicyclo 4.4.0 antiviral derivatives
US7348337B2 (en) 2002-05-28 2008-03-25 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
US20040063744A1 (en) 2002-05-28 2004-04-01 Tao Wang Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
AU2003273608A1 (en) 2002-06-11 2003-12-22 Bristol-Myers Squibb Company Viral envelope mediated fusion assay
US6900206B2 (en) 2002-06-20 2005-05-31 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic sulfonylureido piperazine derivatives
US20040063746A1 (en) 2002-07-25 2004-04-01 Alicia Regueiro-Ren Indole, azaindole and related heterocyclic ureido and thioureido piperazine derivatives
US20050075364A1 (en) * 2003-07-01 2005-04-07 Kap-Sun Yeung Indole, azaindole and related heterocyclic N-substituted piperazine derivatives
EA200600225A1 (ru) 2003-08-14 2006-08-25 Пфайзер Инк. Производные пиперазина для лечения вич инфекций
US20050124623A1 (en) 2003-11-26 2005-06-09 Bender John A. Diazaindole-dicarbonyl-piperazinyl antiviral agents
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US20050215544A1 (en) 2004-03-24 2005-09-29 Pin-Fang Lin Methods of treating HIV infection
US7776863B2 (en) 2004-03-24 2010-08-17 Bristol-Myers Squibb Company Methods of treating HIV infection
US20050215543A1 (en) 2004-03-24 2005-09-29 Pin-Fang Lin Methods of treating HIV infection
US7449476B2 (en) 2004-05-26 2008-11-11 Bristol-Myers Squibb Company Tetrahydrocarboline antiviral agents
US7087610B2 (en) 2004-06-03 2006-08-08 Bristol-Myers Squibb Company Benzothiazole antiviral agents
WO2005121094A1 (en) 2004-06-09 2005-12-22 Pfizer Limited Piperazine and piperidine derivatives as anti-hiv-agents
US20060100209A1 (en) 2004-11-09 2006-05-11 Chong-Hui Gu Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US20060100432A1 (en) 2004-11-09 2006-05-11 Matiskella John D Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US7183284B2 (en) 2004-12-29 2007-02-27 Bristol-Myers Squibb Company Aminium salts of 1,2,3-triazoles as prodrugs of drugs including antiviral agents
US7396830B2 (en) 2005-10-04 2008-07-08 Bristol-Myers Squibb Company Piperazine amidines as antiviral agents
US7501419B2 (en) 2006-04-25 2009-03-10 Bristol-Myers Squibb Company 4-Squarylpiperazine derivatives as antiviral agents
US7807671B2 (en) 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
US7504399B2 (en) * 2006-06-08 2009-03-17 Bristol-Meyers Squibb Company Piperazine enamines as antiviral agents
US7572810B2 (en) * 2006-06-08 2009-08-11 Bristol-Myers Squibb Company Alkene piperidine derivatives as antiviral agents

Also Published As

Publication number Publication date
IL194540A (en) 2015-03-31
AU2007242989A1 (en) 2007-11-08
TWI394754B (zh) 2013-05-01
KR20090005393A (ko) 2009-01-13
TW200811174A (en) 2008-03-01
US20070249579A1 (en) 2007-10-25
US20080139572A1 (en) 2008-06-12
CA2650382A1 (en) 2007-11-08
WO2007127635A3 (en) 2008-03-13
AR060658A1 (es) 2008-07-02
US7807671B2 (en) 2010-10-05
US7807676B2 (en) 2010-10-05
KR101450349B1 (ko) 2014-10-14
AU2007242989B2 (en) 2012-06-28
JP2009535352A (ja) 2009-10-01
IL194540A0 (en) 2009-08-03
NO341412B1 (no) 2017-10-30
NZ571995A (en) 2011-11-25
EA200802203A1 (ru) 2009-04-28
JP5214590B2 (ja) 2013-06-19
ES2432758T3 (es) 2013-12-05
EA014957B1 (ru) 2011-04-29
MX2008013265A (es) 2008-10-27
CA2650382C (en) 2014-05-27
EP2010525A2 (en) 2009-01-07
PE20080318A1 (es) 2008-04-10
EP2010525B1 (en) 2013-08-28
NO20084257L (no) 2008-11-19
WO2007127635A2 (en) 2007-11-08

Similar Documents

Publication Publication Date Title
JP5214590B2 (ja) 抗ウイルス薬としてのジケト−ピペラジンおよびピペリジン誘導体
AU2003301958B2 (en) Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
JP5433690B2 (ja) 抗−hiv薬としてのジケト縮合アゾロピペリジンおよびアゾロピペラジン
PT1363705E (pt) Composição e actividade antiviral de derivados de piperazina azaindoleoxoacética substituídos
EP2509979A1 (en) Heterocyclic compounds containing a pyrrolopyridine or benzimidazole core
CA2547347C (en) Diazaindole-dicarbonyl-piperazinyl antiviral agents
JP5433691B2 (ja) Hiv結合阻害剤としてのジケトピペリジン誘導体
BRPI0313286B1 (pt) compostos derivados de piperazina azaindoleoxoacética substituida com atividade antiviral e composição que os compreende.
EP1638568A2 (en) Indole, azaindole and related heterocyclic n-substituted piperazine derivatives
CA3218442A1 (en) Targeted protein degradation using bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein
CN101432278B (zh) 作为抗病毒剂的二酮基哌嗪和哌啶衍生物
JP2016515580A (ja) Hiv結合阻害剤としての2−ケトアミド誘導体
ES2368430T3 (es) Indol, azaindol y derivados de piperazina n-sustituida heterocíclica relacionados.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: VIIV HEALTHCARE UK (NO.5) LIMITED (GB)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements